Security
Bluejay Diagnostics, Inc. Common Stock · BJDX
BJDXNASDAQCommon stockCurrentCIK 1704287Updated Oct 14, 2026
BJDX price & chart
Loading TradingView…
NASDAQ:BJDX on TradingView ↗About the company
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony™ System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay does not yet have regulatory clearance for the Symphony™ System, and we will need to receive regulatory authorization from the U.S. Food and Drug Administration before Symphony™ can be marketed as a diagnostic product in the United States. Bluejay’s first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from ‘sample-to-result’ to help medical professionals make earlier and better triage/treatment decisions. More information is available at www.bluejaydx.com.
In the news
Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership ↗
SEC disclosures
Bluejay Diagnostics, Inc. files 8-K: Material Event ↗
Recent filings
Regulation FD Disclosure
Items 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Entry into a Material Definitive Agreement · Regulation FD Disclosure
Items 1.01, 7.01, 9.01
4 filing
4 filing
Show 5 more recent filings
4 filing
Regulation FD Disclosure
Items 7.01, 9.01
S-8 filing
10-Q filing
Regulation FD Disclosure
Items 7.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 7,119,237Source | 6,657,423Source | 4,868,531Source | 13,521,265Source |
| Property, Plant and Equipment, NetUSD | 1,534,441Source | 1,513,495Source | 1,285,741Source | 1,232,070Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 5,164,875Source | 4,301,945Source | 2,208,516Source | 10,114,990Source |
| Assets, CurrentUSD | 5,463,602Source | 4,898,883Source | 3,220,860Source | 11,788,470Source |
| Prepaid Expense and Other Assets, CurrentUSD | 275,957Source | 596,938Source | 747,263Source | 1,673,480Source |
| Operating Lease, Right-of-Use AssetUSD | 113,289Source | 209,788Source | 333,267Source | 465,514Source |
| Other Assets, NoncurrentUSD | 7,905Source | 35,257Source | 28,663Source | 35,211Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 1,143,948Source | 927,924Source | 1,973,683Source | 1,979,992Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 60Source | 55Source | 124Source | 2,022Source |
| Additional Paid in CapitalUSD | — | — | — | 28,536,353Source |
| Retained Earnings (Accumulated Deficit)USD | -41,517,267Source | -34,668,784Source | -26,950,990Source | -16,997,102Source |
| Stockholders' Equity Attributable to ParentUSD | 5,975,289Source | 5,729,499Source | 2,894,848Source | 11,541,273Source |
| Additional Paid in Capital, Common StockUSD | 47,492,496Source | 40,398,228Source | 29,845,714Source | — |
| Liabilities and EquityUSD | 7,119,237Source | 6,657,423Source | 4,868,531Source | 13,521,265Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 1,119,197Source | 810,368Source | 1,771,375Source | 1,640,254Source |
| Operating Lease, Liability, CurrentUSD | 100,000Source | 113,260Source | 162,990Source | 168,706Source |
| Accounts Payable, CurrentUSD | 214,255Source | 145,122Source | 491,474Source | 635,818Source |
| Operating Lease, Liability, NoncurrentUSD | 20,211Source | 108,989Source | 189,987Source | 323,915Source |
| Other Liabilities, NoncurrentUSD | 4,540Source | 8,567Source | 12,321Source | 15,823Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 804,942Source | 551,986Source | 1,116,911Source | 835,730Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 6Source | 20,094Source | 189,245Source | 433,004Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 69,133Source | -346,352Source | -235,760Source | 298,881Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -6,053,575Source | -7,819,769Source | -8,313,870Source | -7,741,593Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -173,735Source | -306,783Source | -704,166Source | -1,199,270Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 173,735Source | 306,783Source | 704,166Source | 1,199,270Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | 59,078Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 7,090,240Source | 10,219,981Source | 1,111,562Source | 8,075Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | -8,932,788Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 5,164,875Source | 4,301,945Source | 2,208,516Source | — |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | 364Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 6Source | 20,094Source | 189,245Source | 433,004Source |
| Amortization of Debt Issuance CostsUSD | — | — | — | 183,194Source |
| DepreciationUSD | 74,182Source | 75,618Source | 648,708Source | — |
| Equipment ExpenseUSD | 9,549Source | — | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | -3,411Source | — | -137Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | 6,360Source |
| General and Administrative ExpenseUSD | 3,906,524Source | 3,689,648Source | 4,313,200Source | 4,763,114Source |
| InterestExpenseNonoperatingUSD | 839Source | 823,028Source | — | — |
| Investment Income, InterestUSD | 97,559Source | 145,823Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -6,848,483Source | -7,717,794Source | -9,953,888Source | -9,296,948Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -6,848,483Source | -20,940,847Source | — | — |
| Nonoperating Income (Expense)USD | 104,489Source | -548,178Source | 357,329Source | 20,828Source |
| Operating ExpensesUSD | 6,952,972Source | 7,169,616Source | 10,311,217Source | 9,366,687Source |
| Operating Lease, ExpenseUSD | — | — | — | 168,706Source |
| Other Nonoperating Income (Expense)USD | 7,769Source | — | 192,429Source | — |
| Payments of Financing CostsUSD | 4,027Source | 4,807Source | 4,807Source | 801Source |
| Proceeds from Issuance of Common StockUSD | 8,346,692Source | 12,069,075Source | 1,590,840Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | 28,876Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | — | — | — | 249,040Source |
| Cost of RevenueUSD | — | — | — | 200,129Source |
| Selling, General and Administrative ExpenseUSD | — | — | 283,443Source | — |
| Operating Income (Loss)USD | -6,952,972Source | -7,169,616Source | -10,311,217Source | -9,317,776Source |
| Other Nonoperating Income (Expense)USD | 7,769Source | — | 192,429Source | — |
| Net Income (Loss) Attributable to ParentUSD | -6,848,483Source | -7,717,794Source | -9,953,888Source | -9,296,948Source |
| Earnings Per Share, BasicUSD per share | -15.25Source | -114.19Source | -9.08Source | -0.46Source |
| Earnings Per Share, DilutedUSD per share | -15.25Source | -114.19Source | -9.08Source | -0.46Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 449,043Source | 183,392Source | 1,096,500Source | 20,163,915Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 449,043Source | 183,392Source | 1,096,500Source | 20,163,915Source |
| Interest Expense (non-operating)USD | 839Source | 823,028Source | — | — |
| Additional Financial Items | ||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | 156,598Source |
| Equipment ExpenseUSD | 9,549Source | — | — | — |
| General and Administrative ExpenseUSD | 3,906,524Source | 3,689,648Source | 4,313,200Source | 4,763,114Source |
| Gross ProfitUSD | — | — | — | 48,911Source |
| Interest Income, OtherUSD | — | — | 164,900Source | — |
| Investment Income, InterestUSD | 97,559Source | 145,823Source | — | — |
| Investment Income, NetUSD | 97,559Source | 145,823Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -6,848,483Source | -20,940,847Source | — | — |
| Nonoperating Income (Expense)USD | 104,489Source | -548,178Source | 357,329Source | 20,828Source |
| Operating ExpensesUSD | 6,952,972Source | 7,169,616Source | 10,311,217Source | 9,366,687Source |
| Operating Lease, ExpenseUSD | — | — | — | 168,706Source |
| Other IncomeUSD | — | — | — | 258,137Source |
| Research and Development ExpenseUSD | 3,046,448Source | 3,471,671Source | 5,714,574Source | 4,152,152Source |
| Selling and Marketing ExpenseUSD | — | 8,297Source | — | 451,421Source |
Offerings
Registration 333-296866
Filing attachments
ea030840101ex99-1.htm · 8-K · 2026-10-13
Exhibit 99.1 Bluejay Achieves Toray Contractual Manufacturing Milestone, Advancing Supply-Chain Resilience and Commercialization Readiness Company Achieves Toray Contractual Milestone with Establishment of Manufacturing Site ACTON, Mass. October 13, 2026 - Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on improving patient outcomes through its Symphony™ near-patient diagnostic platform, today announced that it has completed the est…
Read attachment ↗ea030776901ex99-1.htm · 8-K · 2026-10-06
Exhibit 99.1 For Immediate Release Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock. SYMON-II Clinical Validation Dataset Represents a Key Milestone as Bluejay Advances the Symphony™ IL-6 Test Toward Regulatory Submission ACTON, Mass. October 6, 2026 - Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on improving patient outcomes through its Symphony™ …
Read attachment ↗ea030486401ex99-1.htm · 8-K · 2026-09-08
EX-99.1 3 ea030486401ex99-1.htm PRESS RELEASE, DATED SEPTEMBER 8, 2026 Exhibit 99.1 Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets Partnership Establishes Federal Distribution and Co-Marketing Framework Across VA, DoD, Military Health Systems and Other Government Healthcare Channels ACTON, Mass. and PENSACOLA, Fla. - September 8, 2026 - Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a med…
Read attachment ↗ea030188801ex99-1.htm · 8-K · 2026-08-13
EX-99.1 2 ea030188801ex99-1.htm PRESS RELEASE, DATED AUGUST 13, 2026 Exhibit 99.1 Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization SYMON-II pivotal clinical study completes targeted enrollment of 750 patients Company advances toward planned 510(k) submission and commercialization with US manufacturing contract signed to mitigate supply-chain risk Company ends second …
Read attachment ↗ea029895501ex99-1.htm · 8-K · 2026-07-22
EX-99.1 2 ea029895501ex99-1.htm PRESS RELEASE, DATED JULY 21, 2026 Exhibit 99.1 Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study 750 Patients Enrolled Ahead of Plan in Pivotal Study Evaluating Symphony™ IL-6 for Early Assessment of 28-Day Sepsis Mortality Risk ACTON, Mass., July 21, 2026 - Bluejay Diagnostics, Inc. (NASDAQ: BJDX), a medical diagnostics company developing rapid, near-patient diagnostic technologies for …
Read attachment ↗ea029339001ex4-1.htm · 8-K · 2026-06-08
EX-4.1 2 ea029339001ex4-1.htm FORM OF PRE-FUNDED WARRANT Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES A…
Read attachment ↗